China’s NDRC Launches National Lab To Research Therapeutic Vaccines
This article was originally published in PharmAsia News
China’s NDRC launched a national engineering lab for therapeutic vaccines on June 7 at Fudan University, with the first planned effort of research a therapeutic vaccine for Hepatitis B.
You may also be interested in...
Recent executive changes in the industry include C-suite changes at Solid Biosciences and Merck & Co. Meanwhile, new directors were appointed at Allergy Therapeutics and Synairgen.
The US firm’s adagrasib regimen has failed to differentiate itself from Keytruda plus chemotherapy in two early mNSCLC trials but Mirati is nonetheless forging ahead with pivotal development, albeit with strictly defined populations.
Haleon’s UK and Ireland general manager Bas Vorsteveld becomes PAGB president, replacing Perrigo's Neil Lister. Lister reflects on a turbulent four years chairing the UK industry association.